E
AREV Life Sciences Global Corp.
AREVF
$0.01
$0.005100.00%
E
Sell
12/13/2023Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to E+ from E on 12/13/2023 due to a large increase in the growth index and solvency index. Operating cash flow increased 95.13% from -$86.2 to -$4.2, EBIT increased 89.6% from -$85.6 to -$8.9, and earnings per share increased from -$0.0028 to -$0.0007.
AREV Life Sciences Global Corp. (AREVF) was upgraded to E+ from E on 12/13/2023 due to a large increase in the growth index and solvency index. Operating cash flow increased 95.13% from -$86.2 to -$4.2, EBIT increased 89.6% from -$85.6 to -$8.9, and earnings per share increased from -$0.0028 to -$0.0007.
E
Sell
12/4/2023Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to E from E+ on 12/4/2023 due to a significant decline in the growth index, valuation index and total return index. Operating cash flow declined 400% from -$3.7 to -$18.5, earnings per share declined from $0.0019 to -$0.0039, and EBIT declined 274.67% from $67.5 to -$117.9.
AREV Life Sciences Global Corp. (AREVF) was downgraded to E from E+ on 12/4/2023 due to a significant decline in the growth index, valuation index and total return index. Operating cash flow declined 400% from -$3.7 to -$18.5, earnings per share declined from $0.0019 to -$0.0039, and EBIT declined 274.67% from $67.5 to -$117.9.
E
Sell
3/14/2023Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D on 03/14/2023.
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from E+ on 02/09/2023.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from -0.08 to -0.06.
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, valuation index and solvency index. Debt to equity increased from -0.08 to -0.06.
D
Sell
8/18/2022Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 8/18/2022 due to a large increase in the growth index, solvency index and valuation index. Operating cash flow increased 20.68% from -$126.2 to -$100.1, and total revenue increased 17.65% from $6.8 to $8.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 8/18/2022 due to a large increase in the growth index, solvency index and valuation index. Operating cash flow increased 20.68% from -$126.2 to -$100.1, and total revenue increased 17.65% from $6.8 to $8.
D
Sell
8/16/2022Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 8/16/2022 due to a decline in the total return index and valuation index.
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 8/16/2022 due to a decline in the total return index and valuation index.
D
Sell
8/1/2022Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 8/1/2022 due to an increase in the total return index.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 8/1/2022 due to an increase in the total return index.
D
Sell
7/14/2022Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 7/14/2022 due to a noticeable decline in the total return index and volatility index.
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 7/14/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
5/31/2022Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to D from D+ on 5/31/2022 due to a major decline in the solvency index and growth index. Earnings per share declined from $0.063 to -$0.0144, total revenue declined 93.97% from $112.7 to $6.8, and the quick ratio declined from 0.4 to 0.07.
AREV Life Sciences Global Corp. (AREVF) was downgraded to D from D+ on 5/31/2022 due to a major decline in the solvency index and growth index. Earnings per share declined from $0.063 to -$0.0144, total revenue declined 93.97% from $112.7 to $6.8, and the quick ratio declined from 0.4 to 0.07.
D
Sell
5/27/2022Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D+ from D on 5/27/2022 due to a significant increase in the valuation index, total return index and volatility index.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D+ from D on 5/27/2022 due to a significant increase in the valuation index, total return index and volatility index.
D
Sell
5/16/2022Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from E+ on 05/16/2022.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D+ on 5/13/2022 due to a significant decline in the valuation index and total return index.
AREV Life Sciences Global Corp. (AREVF) was downgraded to E+ from D+ on 5/13/2022 due to a significant decline in the valuation index and total return index.
D
Sell
5/4/2022Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D+ from D- on 5/4/2022 due to a significant increase in the valuation index, growth index and solvency index. Earnings per share increased from -$0.0069 to $0.063, total revenue increased 436.67% from $21 to $112.7, and the quick ratio increased from 0.09 to 0.4.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D+ from D- on 5/4/2022 due to a significant increase in the valuation index, growth index and solvency index. Earnings per share increased from -$0.0069 to $0.063, total revenue increased 436.67% from $21 to $112.7, and the quick ratio increased from 0.09 to 0.4.
D
Sell
4/20/2022Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index. Total revenue declined 40.34% from $35.2 to $21.
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index. Total revenue declined 40.34% from $35.2 to $21.
D
Sell
11/23/2021Upgraded
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 11/23/2021.
AREV Life Sciences Global Corp. (AREVF) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 11/8/2021 due to a substantial decline in the growth index and valuation index. Operating cash flow declined 74.39% from -$388.9 to -$678.2, EBIT declined 25.23% from -$433.3 to -$542.6, and earnings per share declined from -$0.0206 to -$0.0225.
AREV Life Sciences Global Corp. (AREVF) was downgraded to D- from D on 11/8/2021 due to a substantial decline in the growth index and valuation index. Operating cash flow declined 74.39% from -$388.9 to -$678.2, EBIT declined 25.23% from -$433.3 to -$542.6, and earnings per share declined from -$0.0206 to -$0.0225.
D
Sell
11/27/2020Upgraded
AREV NanoTec Brands Inc. (AREVF) was upgraded to D from D- on 11/27/2020 due to a large increase in the growth index, volatility index and solvency index. Operating cash flow increased 94.19% from -$239.4 to -$13.9, EBIT increased 49.24% from -$178.7 to -$90.7, and earnings per share increased from -$0.0123 to -$0.0067.
AREV NanoTec Brands Inc. (AREVF) was upgraded to D from D- on 11/27/2020 due to a large increase in the growth index, volatility index and solvency index. Operating cash flow increased 94.19% from -$239.4 to -$13.9, EBIT increased 49.24% from -$178.7 to -$90.7, and earnings per share increased from -$0.0123 to -$0.0067.
D
Sell
8/28/2020Downgrade
AREV NanoTec Brands Inc. (AREVF) was downgraded to D- from D on 8/28/2020 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 567.58% from $51.2 to -$239.4, EBIT declined 167.51% from -$66.8 to -$178.7, and earnings per share declined from -$0.0089 to -$0.0144.
AREV NanoTec Brands Inc. (AREVF) was downgraded to D- from D on 8/28/2020 due to a decline in the growth index, volatility index and valuation index. Operating cash flow declined 567.58% from $51.2 to -$239.4, EBIT declined 167.51% from -$66.8 to -$178.7, and earnings per share declined from -$0.0089 to -$0.0144.
D
Sell
7/13/2020Upgraded
AREV NanoTec Brands Inc. (AREVF) was upgraded to D from D- on 7/13/2020 due to a major increase in the growth index, solvency index and total return index. The quick ratio increased from 0.04 to 0.16, EBIT increased 92.16% from -$852.4 to -$66.8, and earnings per share increased from -$0.1032 to -$0.0089.
AREV NanoTec Brands Inc. (AREVF) was upgraded to D from D- on 7/13/2020 due to a major increase in the growth index, solvency index and total return index. The quick ratio increased from 0.04 to 0.16, EBIT increased 92.16% from -$852.4 to -$66.8, and earnings per share increased from -$0.1032 to -$0.0089.
D
Sell
6/26/2020Upgraded
AREV NanoTec Brands Inc. (AREVF) was upgraded to D- from E+ on 6/26/2020 due to an increase in the volatility index and total return index.
AREV NanoTec Brands Inc. (AREVF) was upgraded to D- from E+ on 6/26/2020 due to an increase in the volatility index and total return index.
E
Sell
6/15/2020Downgrade
AREV NanoTec Brands Inc. (AREVF) was downgraded to E+ from D- on 6/15/2020 due to a decline in the volatility index.
AREV NanoTec Brands Inc. (AREVF) was downgraded to E+ from D- on 6/15/2020 due to a decline in the volatility index.
D
Sell
5/29/2020Upgraded
AREV NanoTec Brands Inc. (AREVF) was upgraded to D- from E+ on 5/29/2020 due to an increase in the volatility index.
AREV NanoTec Brands Inc. (AREVF) was upgraded to D- from E+ on 5/29/2020 due to an increase in the volatility index.
E
Sell
5/6/2020Downgrade
AREV NanoTec Brands Inc. (AREVD) was downgraded to E+ from D- on 5/6/2020 due to a noticeable decline in the efficiency index, solvency index and volatility index.
AREV NanoTec Brands Inc. (AREVD) was downgraded to E+ from D- on 5/6/2020 due to a noticeable decline in the efficiency index, solvency index and volatility index.
D
Sell
1/2/2020Upgraded
AREV Brands International Ltd. (AREVF) was upgraded to D- from E on 1/2/2020 due to an increase in the growth index, efficiency index and valuation index. Operating cash flow increased 119.89% from -$174.5 to $34.7, earnings per share increased from -$0.0209 to -$0.0035, and net income increased 82.98% from -$1.13M to -$192.1.
AREV Brands International Ltd. (AREVF) was upgraded to D- from E on 1/2/2020 due to an increase in the growth index, efficiency index and valuation index. Operating cash flow increased 119.89% from -$174.5 to $34.7, earnings per share increased from -$0.0209 to -$0.0035, and net income increased 82.98% from -$1.13M to -$192.1.
E
Sell
10/1/2019Upgraded
AREV Brands International Ltd. (AREVF) was upgraded to E from E- on 10/1/2019 due to an increase in the growth index and valuation index.
AREV Brands International Ltd. (AREVF) was upgraded to E from E- on 10/1/2019 due to an increase in the growth index and valuation index.
E
Sell
7/24/2019None
AREV Life Sciences Global Corp. (AREVF) was downgraded to E- from U on 07/24/2019.
AREV Life Sciences Global Corp. (AREVF) was downgraded to E- from U on 07/24/2019.
OTC PK
04/17/2024 10:41AM Eastern
Quotes delayed
